NADH vs. NAD+: What's the Difference, and Does It Matter for a Supplement?

Written by the Nuvirox Research Team

Short answer: they are the same molecule, and the difference is two electrons and a proton. NAD+ is the oxidized form, ready to accept electrons. NADH is the reduced form, carrying them. Cells convert between the two thousands of times a second. Buying “NADH” instead of an NAD+ precursor is not obviously an upgrade, and the human evidence for it is smaller than the marketing implies.

This confuses people constantly, partly because supplement labels use “NAD,” “NAD+,” and “NADH” almost interchangeably when they are describing meaningfully different chemistry.

Simplified schematic of redox cycling. The pool is recycled continuously; the same molecules make this round trip many times per second in metabolically active tissue.

Why does the ratio matter more than the amount?

Because the ratio is the signal. A high NAD+/NADH ratio tells the cell it has capacity to burn fuel; a low ratio tells it the electron carriers are backed up. Enzymes read this ratio and adjust behaviour accordingly.

Sirtuins, for instance, require NAD+ specifically — not NADH. So does PARP, the DNA repair enzyme family. Both consume NAD+ rather than recycling it, which is part of why the pool needs constant replenishment, a process we cover in our piece on the NAD+ salvage pathway.

This is why simply flooding a cell with NADH is not the obvious win it sounds like. In some contexts you would be pushing the ratio in the direction that signals energetic congestion.

Does the NAD+ pool actually decline with age?

Tissue measurements generally point that way, though the size of the drop varies enormously by tissue and by measurement method. Consumption appears to be a bigger driver than production failure — the enzyme CD38 becomes more active with age and degrades NAD+, which we cover separately in the article on CD38.

What is far less clear is whether the NADH side of the pool declines proportionally, and whether the ratio shifts in any consistent direction across human tissues. Studies that measure both are much rarer than studies that measure NAD+ alone.

What human studies actually show

The original NADH fatigue signal came from a small crossover pilot. A 1999 study gave oral NADH to patients with chronic fatigue syndrome in a placebo-controlled crossover design. The authors reported symptomatic benefit and concluded NADH might be a useful adjunct, explicitly calling for larger trials to establish efficacy. That was a pilot study, and it was the foundation for most of the NADH supplement category that followed.

The larger follow-ups tested NADH combined with CoQ10, which is a real interpretive problem. An 8-week randomized, double-blind, placebo-controlled trial in 73 patients with chronic fatigue syndrome used 200 mg CoQ10 plus 20 mg NADH daily. It reported a significant reduction in fatigue impact scores versus placebo, alongside increases in measured NAD+/NADH, CoQ10, and ATP in blood mononuclear cells. A separate 8-week trial in 80 patients found effects on maximum heart rate after exercise testing.

The largest of these trials was 207 people over 12 weeks — and its headline findings were within-group. That trial randomized patients with ME/CFS to CoQ10 plus NADH or placebo. Significant improvements in cognitive fatigue perception and quality of life were reported within the experimental group over time. Within-group improvement is a weaker form of evidence than a between-group difference, because it does not separate the treatment from regression to the mean or expectation effects.

By contrast, the NAD+ precursor trials are cleaner on the pharmacokinetics. An open-label pharmacokinetic study established that oral nicotinamide riboside raises blood NAD+ in healthy volunteers, and a randomized crossover trial confirmed the effect over six weeks at 1,000 mg per day with good tolerability. That is a narrower claim than “it fixes fatigue,” but it is a well-supported one.

What NADH supplements won't do

They will not out-compete the recycling system. Your cells interconvert NAD+ and NADH continuously; a capsule taken once a day is a rounding error against that flux unless it changes the total pool size.

They also will not resolve fatigue that has a medical cause. Persistent tiredness with a plausible medical explanation — unexplained weight change, breathlessness, snoring with witnessed pauses, heavy periods, new depression — deserves a workup. See a doctor if that describes you.

And they will not necessarily survive your stomach intact. NADH is less chemically stable than its oxidized counterpart in acidic conditions, which is why NADH products often use stabilised or enteric formats. Whether those formats deliver meaningfully more to tissue is not well established in published human data.

If you are choosing between them, how should you think about dose?

The NADH fatigue trials clustered around 10–20 mg per day, typically alongside 200 mg CoQ10. The precursor trials used much larger numbers — 250 to 2,000 mg per day for nicotinamide riboside, with 1,000 mg the most commonly studied and 300–500 mg the most common commercial dose.

Those numbers are not comparable, because they are different molecules doing different jobs. If you want the precursor comparison specifically, we lay it out in NR vs. NMN vs. NAD+.

Give any of them a fair evaluation window. The published trials ran six to twelve weeks, and the ones that found effects generally did not find them at two weeks.

Frequently asked questions

Is NADH better than NAD+ for energy?

There is no good human evidence that it is. The NADH fatigue trials are small and used combination products; the NAD+ precursor trials are larger and cleaner on pharmacokinetics but have not consistently shown fatigue benefits in healthy people. Neither has earned a clear win.

Can you take NADH and an NAD+ precursor together?

There is no published trial testing that combination, so any answer is speculation. If you are considering stacking supplements, that is a reasonable thing to run past a pharmacist, especially if you take prescription medication.

Does NADH raise NAD+ levels?

In principle the two interconvert, so raising one should influence the pool. In practice, published human pharmacokinetic data for oral NADH is much thinner than for nicotinamide riboside, where the blood NAD+ rise is well documented.

Why do labels say NAD+ if you cannot absorb NAD+ directly?

Marketing, mostly. Intact NAD+ is a large molecule that is generally thought to be broken down before absorption, which is why the well-studied oral products are precursors rather than NAD+ itself. We cover the delivery-format claims in our piece on liposomal NAD+.

From Nuvirox

Why we formulated NAD+ Restore.

Every two-capsule serving delivers 500 mg of nicotinamide riboside chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.

It also includes 150 mg trans-resveratrol from Japanese knotweed and 50 mg quercetin from Sophora japonica — polyphenols studied alongside NAD+ pathways for cellular health support — plus 10 mg galactomannans from fenugreek to support absorption.

It ships with a 60-day money-back guarantee, which is long enough to actually evaluate it the way the research says you should.

Learn more about NAD+ Restore →

The bottom line

NAD+ and NADH are two faces of one molecule, and the interesting biology is in the ratio between them rather than in either number alone. The fair reading of the human literature is that NADH has a small, combination-product evidence base concentrated in chronic fatigue syndrome, while NAD+ precursors have a larger, cleaner evidence base that establishes they raise NAD+ without yet establishing what that reliably does for how you feel.

References

1. Forsyth LM, Preuss HG, MacDowell AL, Chiazze L Jr, Birkmayer GD, Bellanti JA. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol. 1999;82(2):185–191. doi:10.1016/S1081-1206(10)62595-1. PMID: 10071523.
2. Castro-Marrero J, Cordero MD, Segundo MJ, et al. Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome? Antioxid Redox Signal. 2015;22(8):679–685. doi:10.1089/ars.2014.6181. PMID: 25386668; PMCID: PMC4346380.
3. Castro-Marrero J, Sáez-Francàs N, Segundo MJ, et al. Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome — a randomized, controlled, double-blind trial. Clin Nutr. 2016;35(4):826–834. doi:10.1016/j.clnu.2015.07.010. PMID: 26212172.
4. Castro-Marrero J, Segundo MJ, Lacasa M, et al. Effect of dietary coenzyme Q10 plus NADH supplementation on fatigue perception and health-related quality of life in individuals with ME/CFS: a prospective, randomized, double-blind, placebo-controlled trial. Nutrients. 2021;13(8):2658. doi:10.3390/nu13082658. PMCID: PMC8399248.
5. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286. doi:10.1038/s41467-018-03421-7.
6. Airhart SE, Shireman LM, Risler LJ, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017;12(12):e0186459. doi:10.1371/journal.pone.0186459.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.